NASDAQ:BCYC Bicycle Therapeutics (BCYC) Stock Price, News & Analysis $4.20 -0.15 (-3.36%) Closing price 03:58 PM EasternExtended Trading$4.21 +0.01 (+0.14%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Bicycle Therapeutics Stock (NASDAQ:BCYC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Bicycle Therapeutics alerts:Sign Up Key Stats Today's Range$4.21▼$4.3850-Day Range$3.96▼$5.1552-Week Range$3.92▼$9.18Volume192,385 shsAverage Volume439,705 shsMarket Capitalization$293.48 millionP/E RatioN/ADividend YieldN/APrice Target$14.00Consensus RatingHold Company Overview Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology. Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners. Its oncology portfolio includes targeted agents aimed at tumor-associated receptors and tumor-penetrating ligands designed to deliver therapeutic payloads. In parallel, the company is advancing candidates in neuroscience and immuno-oncology, seeking to address high-unmet-need conditions. Bicycle’s programs are being evaluated in preclinical and early clinical studies, and the company has established research collaborations with several global biopharmaceutical organizations to accelerate the clinical development of its lead molecules. Headquartered in Cambridge, UK, Bicycle Therapeutics has expanded its presence with operations in the United States to support its growing clinical activities and partnerships. The company is led by an experienced management team with deep expertise in peptide chemistry, translational research and drug development. By integrating its proprietary platform with strategic alliances, Bicycle Therapeutics aims to advance a new class of precision medicines capable of reaching challenging therapeutic targets with improved safety and efficacy profiles.AI Generated. May Contain Errors. Read More Bicycle Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreBCYC MarketRank™: Bicycle Therapeutics scored higher than 53% of companies evaluated by MarketBeat, and ranked 492nd out of 852 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingHold Consensus RatingBicycle Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on no strong buy ratings, 5 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialBicycle Therapeutics has a consensus price target of $14.00, representing about 230.8% upside from its current price of $4.23.Amount of Analyst CoverageBicycle Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Bicycle Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Bicycle Therapeutics are expected to decrease in the coming year, from ($1.97) to ($1.99) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bicycle Therapeutics is -1.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bicycle Therapeutics is -1.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBicycle Therapeutics has a P/B Ratio of 0.48. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Bicycle Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.36% of the float of Bicycle Therapeutics has been sold short.Short Interest Ratio / Days to CoverBicycle Therapeutics has a short interest ratio ("days to cover") of 4.75.Change versus previous monthShort interest in Bicycle Therapeutics has recently increased by 2.06%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBicycle Therapeutics does not currently pay a dividend.Dividend GrowthBicycle Therapeutics does not have a long track record of dividend growth. News and Social Media2.4 / 5News Sentiment-0.22 News SentimentBicycle Therapeutics has a news sentiment score of -0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Bicycle Therapeutics this week, compared to 3 articles on an average week.Search Interest2 people have searched for BCYC on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Bicycle Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Bicycle Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $42,702.00 in company stock.Percentage Held by Insiders22.00% of the stock of Bicycle Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.15% of the stock of Bicycle Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Bicycle Therapeutics' insider trading history. Receive BCYC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bicycle Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BCYC Stock News HeadlinesBicycle Therapeutics (NASDAQ:BCYC) Stock, Earnings Estimates, EPS, And RevenueJuly 14 at 3:11 AM | benzinga.comBicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Given Average Recommendation of "Hold" by BrokeragesJuly 14 at 2:28 AM | americanbankingnews.comThis Is How Financial Freedom Dies—And Most People Never See It ComingWhile the trade war grabs headlines, the Department of Justice has quietly argued in court that cash may not be legally yours. If Washington can seize imported goods without warning, your bank account could be the next target. Governments rarely announce moves against private wealth in advance. A free Wealth Defense Guide outlines how to move your savings out of reach before the window closes.July 14 at 1:00 AM | Priority Gold (Ad)Insider Selling: Bicycle Therapeutics (NASDAQ:BCYC) CEO Sells 5,905 SharesJuly 8, 2026 | insidertrades.comBicycle Therapeutics: Trading Below Cash Amid Multiple UncertaintiesJune 1, 2026 | seekingalpha.comAnalysts Offer Insights on Healthcare Companies: Bicycle Therapeutics (BCYC) and Option Care Health (OPCH)May 31, 2026 | theglobeandmail.comBicycle Therapeutics Provides Update on Nuzefatide Pevedotin and EphA2 Pipeline at the AACR Annual Meeting 2026April 20, 2026 | businesswire.comRBC Capital lowers its price target on Bicycle Therapeutics plc (BCYC) to $7 from $11April 4, 2026 | msn.comSee More Headlines BCYC Stock Analysis - Frequently Asked Questions How have BCYC shares performed this year? Bicycle Therapeutics' stock was trading at $7.08 at the start of the year. Since then, BCYC stock has decreased by 40.2% and is now trading at $4.2320. How were Bicycle Therapeutics' earnings last quarter? Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) announced its earnings results on Thursday, April, 30th. The company reported ($0.87) earnings per share for the quarter, missing analysts' consensus estimates of ($0.62) by $0.25. The firm earned $0.89 million during the quarter, compared to the consensus estimate of $7.50 million. Bicycle Therapeutics had a negative trailing twelve-month return on equity of 35.74% and a negative net margin of 344.95%. When did Bicycle Therapeutics IPO? Bicycle Therapeutics (BCYC) raised $65 million in an IPO on Thursday, May 23rd 2019. The company issued 4,333,333 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Jefferies and Piper Jaffray acted as the underwriters for the IPO and Canaccord Genuity was co-manager. Who are Bicycle Therapeutics' major shareholders? Bicycle Therapeutics' top institutional shareholders include Marquette Asset Management LLC (0.10%), FNY Investment Advisers LLC (0.04%) and GAMMA Investing LLC (0.01%). Insiders that own company stock include Bros Advisors Lp Baker, Kevin Lee, Alistair Milnes, Michael Skynner, Jennifer Scott Perry, Alethia Young, Santiago Arroyo, Travis Alvin Thompson, Nicholas Keen, Michael Charles Ferguso Hannay, Nigel Crockett and Robert Charles Swanton. View institutional ownership trends. How do I buy shares of Bicycle Therapeutics? Shares of BCYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Bicycle Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bicycle Therapeutics investors own include Vale (VALE), uniQure (QURE), Clean Energy Fuels (CLNE), Paycom Software (PAYC), Curaleaf (CURLF) and Company Calendar Last Earnings4/30/2026Today7/14/2026Next Earnings (Estimated)8/14/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (51m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 BCYC's financial health is in the Red zone, according to TradeSmith. BCYC has been in this zone for over 51 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BCYC CIK1761612 Webwww.bicycletherapeutics.com Phone441223261503FaxN/AEmployees240Year Founded2009Price Target and Rating Average Price Target for Bicycle Therapeutics$14.00 High Price Target$36.00 Low Price Target$7.00 Potential Upside/Downside+232.1%Consensus RatingHold Rating Score (0-4)2.44 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($3.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$218.96 million Net Margins-344.95% Pretax Margin-342.73% Return on Equity-35.74% Return on Assets-29.54% Debt Debt-to-Equity RatioN/A Current Ratio12.66 Quick Ratio12.66 Sales & Book Value Annual Sales$72.86 million Price / Sales4.04 Cash FlowN/A Price / Cash FlowN/A Book Value$8.79 per share Price / Book0.48Miscellaneous Outstanding Shares69,810,000Free Float54,453,000Market Cap$294.25 million OptionableOptionable Beta1.55 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:BCYC) was last updated on 7/14/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredPrint this and keep it by your screenEver been right about a stock's direction and still lost money on the trade? It's almost never bad luck - it's...Profits Run | SponsoredThe 1934 playbookIn 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...American Alternative | SponsoredAmerican’s Biggest Threat Is HereThis feels like one of those ''where were you when Kennedy was shot'' moments. It felt like a moment in time, ...Goldco Direct, LLC | SponsoredElon Is Quietly Doubling Down on This Bizarre AssetYahoo Finance reports this technology 'May Unlock $400 Trillion' - and Bloomberg calls it 'unavoidable.' Elon ...Brownstone Research | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredThe only metrics you should watch as a day trader.Day traders and swing traders don't need the same metrics - and using the wrong ones costs you edge. After 40 ...The TradingPub | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicycle Therapeutics PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicycle Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
